While intra-tumour heterogeneity with regard to mutations conferring resistance to BRAF inhibitors has been reported before (Shi et al, 2014; Van Allen et al, 2014), the study by the Peeper group is the first to highlight the possible complications for PDX studies. Here, BRAF is linked to neoplasm.